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Abstract
Moyamoya disease is a rare, progressive cerebrovascular occlusive disease; 
characterized by narrowing of the distal internal carotid arteries and their 
branches. The incidence is high in East Asians and most commonly presents in 
the first and fourth decade of life. Its symptoms are headaches, seizures, transient 
neurological deficits, and cognitive decline. Medical management is based on 
treating the symptoms and includes antiplatelet and anti-seizure medications. 
Surgical revascularization is the mainstay of treatment. Unique pathophysiology of 
moyamoya disease necessitates neuro-anesthesiologists to formulate an individual-
ized plan perioperatively. The overriding goal of perioperative anesthetic manage-
ment of moyamoya disease is to ensure optimal cerebral perfusion and protection. 
Maintenance of normotension, normocarbia, normo-oxygenation, normothermia, 
and euvolemia is the cornerstone during the perioperative period. Perioperative 
adequate analgesia is crucial to prevent cerebral ischemia and allows close neuro-
logical monitoring. This chapter reviews perioperative anesthetic management of 
patients with moyamoya disease.
Keywords: moyamoya disease, perioperative consideration, anesthetic management, 
indocyanine green, total intravenous anesthesia, scalp nerve block,  
special considerations in non-revascularization surgery
1. Introduction
Moyamoya disease is a unique cerebrovascular condition that is characterized by 
slowly progressive narrowing of the terminal portion of the internal carotid artery 
and its proximal branches. The name of this disease is derived from the dilated and 
fragile distal collateral vessels, which develop over time and demonstrate a charac-
teristic “puff of smoke” appearance (see Figure 1) on cerebral angiography [1, 2]. 
On the other hand, moyamoya syndrome is traditionally considered in patients who 
have the characteristics vasculopathy and associated conditions, such as sickle cell 
disease or neurofibromatosis [3]. The incidence of moyamoya disease (MMD) is 
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high in East Asia, and familial links account for 15% of the patients. It has a bimodal 
distribution which includes two peaks of age distribution at 5 years and 40 years 
[4, 5]. The pathophysiology of MMD is not a well-studied entity. However, genetic 
acquired, and environmental factors have been ascribed. Mutation analysis of the 
RNF213 gene showed a strong correlation with MMD [6]. Histologically, MMD 
results from fibro-cellular thickening of the intimal layer of the cerebral arteries that 
progress to vessel narrowing and secondary vascular proliferation. Traditionally, 
moyamoya disease manifests itself bilaterally; these stenotic lesions are progressive; 
and thus, the patients present for bilateral procedures. Classically, MMD can present 
as transient ischemic attacks (TIA), ischemic or hemorrhagic stroke, headache, 
epilepsy, and cognitive dysfunction with the occurrence of each symptoms vary-
ing depending on the age of the patient. Diagnostic criteria for MMD have been 
established by the Research Committee on Spontaneous Occlusions of the Circle of 
Willis (Moyamoya Disease) of the Ministry of Health and Welfare of Japan [7] and 
are presented in Table 1. In 1969, Takaku and Suzuki developed angiographic stag-
ing to document the progression of MMD [8] as demonstrated in Table 2. Medical 
management is aimed at reducing the risk of stroke or controlling seizures [4, 9]. 
Aspirin or other antiplatelet drugs are recommended to prevent strokes whereas, 
anti-seizure drugs should be prescribed if the patient has a seizure disorder. The 
definitive treatment is surgical, which involves direct or indirect revascularization 
techniques, or a combination of both may be used. Indirect procedures include 
encephaloduroarteriosynangiosis (EDAS) or encephalomyossynangiosis. In a direct 
revascularization procedure, the superficial temporal artery of the scalp is anasto-
mosed directly to a cerebral artery (middle cerebral artery) to increase blood flow to 
the brain [10, 11]. The perioperative management of MMD presents unique chal-
lenges and mandates individualized perioperative strategy [12]. In this chapter, we 
review the perioperative anesthetic considerations for revascularization and non-
revascularization surgery in MMD patients with relevance to the current evidence 
Figure 1. 
Bilateral internal carotid artery narrowing at the bifurcation with characteristic “puff of smoke” collateral 
circulation on cerebral angiography. Picture courtesy of Dr. Jafar (Hamad Medical Corporation).
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base and clinical guidelines. It is aimed to be a comprehensive review for residents 
and fellows training in the field of neuroanaesthesia.
2.  Perioperative anesthetic consideration for revascularization or 
intracranial bypass surgery
Anesthetic considerations for patients with MMD have been described in many 
literatures for both adult and pediatric populations [12–19]. Significant hemodynamic 
changes are expected throughout the perioperative period, and thus, it necessitates 
intensive care management. Hypertension and hypoventilation can potentially result 
in intracranial hemorrhage, likewise, intraoperative hypotension and hyperventilation 
can cause cerebral ischemia. The principles of safe anesthesia in neurosurgery, such 
as normotension, normocarbia, adequate oxygenation, normothermia, and normo-
volemia, are also applicable in revascularization surgery for patients with MMD. The 
anesthetic management of MMD presents unique challenges, as it can ensue further 
complications of the disease. Therefore, in-depth knowledge of pathophysiology and 
institutional guidelines for intraoperative optimal care of MMD patients improves 
perioperative care and long term outcomes [14, 17, 20]. Most of the following discus-
sion highlights general anesthetic consideration in MMD (see Table 3).
Criteria 1. Cerebral Angiography—
must demonstrate at least three of the 
following
i. Stenosis or occlusion of the distal internal carotid artery (ICA) 
or proximal portions of the anterior cerebral artery (ACA) or 
middle cerebral artery (MCA)
ii. Abnormal vascular networks near the stenotic lesions
iii. Bilateral findings
Criteria 2. If MRI and MRA 
demonstrate all of the following 
criteria, angiography can be deferred
i. Stenosis or occlusion of the distal ICA or proximal portions of 
the ACA or MCA
ii. Abnormal vascular networks in the basal ganglia
iii. Bilateral findings





vi. Von Recklinghausen’s disease
vii. Head injury
viii. Cerebrovascular lesions after head irradiation
Table 1. 
Diagnostic criteria for Moyamoya disease [7].
Stage 1 • Stenosis of suprasellar ICA, usually bilateral
Stage 2 • Development of moyamoya vessels at base of brain
Stage 3 • Increasing ICA stenosis and prominence of moyamoya vessels
Stage 4 • Entire circle of Willis and PCAs occluded, extracranial collaterals start to appear, 
moyamoya vessels begin to diminish
Stage 5 • Further progression of stage 4 with progressive reduction of moyamoya vessels
Stage 6 • Complete absence of moyamoya vessels and major cerebral arteries
Table 2. 
Angiographic staging for progression of MMD [8].
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Preoperative • Evaluate cerebral ischemic risks, preexisting neurological deficits, stage of hemody-
namic failure and adequacy of collateral circulation
• Continue anti-seizure medication and perioperative anticoagulation/antiplatelet 
therapy decisions based on multidisciplinary team
Intraoperative • Anesthetic goals: Maintenance of adequate cerebral perfusion and hemodynamic 
stability, ventilation to maintain normocarbia, and normothermia
• Blood pressure goals: normotensive (Mean arterial pressue within 10–20% of 
preoperative baseline) and increase during temporary occlusion with vasopressors 
support (preferrable noradrenaline infusion)
• Avoid dehydration, and target hematocrit around 35%
• Adequate analgesia and scalp block (before mayfield pin placement)
• Smooth emergence and avoid coughing on extubation
• Balance ansethesia technique to facilitate immediate postoperative neurological 
assessment
Postoperative • Patient admitted to intensive care unit for hemodynamic and neurological 
monitoring
• Pain control with acetaminophen and postoperative sedation with fentanyl and 
dexmedetomidine also good choice
• Ensure graft function and avoid hyperperfusion
• Resume antiplatelet or anticoagulation
Table 3. 
Perioperative considerations for revascularization surgery.
2.1 Preoperative anesthetic evaluation and premedication
Preoperative anesthetic assessment is paramount in reducing the complica-
tions associated with MMD and improving the surgical outcome. It must include 
detailed general medical, surgical history, physical exam, and assessment 
for signs and symptoms associated with MMD and coexisting comorbidities. 
Patients with MMD may have a significant preexisting neurologic deficit. 
Depending on the mode of presentation, hypertension can occur as a result of 
cerebral vascular incompetency. Inadequate treatment of hypertension may lead 
to perioperative cerebral infarction or stroke. History of frequent preoperative 
transient ischemic attacks indicates compromised cerebral collateral circulation 
and is a significant risk factor for perioperative complications [21–23]. Chronic 
cerebral ischemia may lead to neurologic deficits such as motor deficit, epilepsy, 
and mental retardation. MMD is linked to other medical conditions, includ-
ing cardiovascular and renal systems, which have a direct impact on anesthetic 
management and postoperative outcomes. A multidisciplinary strategy is vital 
to improve the perioperative outcome and avoid complications, necessitating 
a high level of collaboration and communication with the surgeon. Suggested 
criteria in the selection of adult MMD patients for cerebral revascularization [17] 
(see Table 4). Thus, preoperative assessment allows early recognition of high-
risk patients and reciprocal identification of the potential perioperative issues, 
and adequate preparation to deal with the challenges. In summary, the goal of 
preoperative anesthesia assessment involves recognizing risk factors for cerebral 
ischemia, pre-existing neurological deficits, degree of hemodynamic failure, 
adequacy of collateral circulation and vascular risk factors (diabetes, cardiovas-
cular disease, hypertension), and optimize the patient’s condition before surgery.
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2.1.1 Preoperative investigation and imaging studies
Baseline preoperative laboratory investigation include a complete blood count, 
serum electrolytes, blood urea nitrogen, creatinine, glucose, and coagulation 
profile. An electrocardiogram (ECG), Echocardiogram, chest x-ray, and arterial 
blood gases may also be obtained. ECG abnormalities in MMD include ventricular 
enlargement and hypertrophy, ST-T wave changes, premature ventricular con-
traction, and right and left axis deviation [24–26]. A review of imaging studies 
especially cerebral angiography may help to identify the severity of the disease.
2.1.2 The Berlin moyamoya grading
It incorporated digital subtraction angiography, MRI, and cerebrovascular reserve 
capacity (CVRC) which allows to stratify clinical symptomatology and provides 
information on cerebrovascular function. Czabanka et al. propose the grading system 
which has three grades [27] (see Table 5).
2.1.3 Premedication
It is essential to review the chronic medical conditions of a patient with MMD. 
Review of medications is a vital part of anesthesia evaluation. Calcium channel 
• Functional status: patient is able to perform activities of daily living (modified Rankin Scale>3)
• Neurological presentation: patient has recurrent (sensorymotor, speech, visual or gait disturbance) or 
progressive (crescendo focal deficit or global cognitive decline) neurological deficit(s) due to repeated 
TIAs, cerebral infarctions, cerebral hemorrhages or severe chronic hypoperfusion. The procedure is 
delayed for at least 6 weeks after the last cerebral infarction/haemorrhage
• Radiological features: the angiographic stage of the disease is Suzuki’s stage II to IV
• Cerebral blood flow studies: dedicated imaging studies show at least significant hypoperfusion of  
the involve hemisphere or corresponding cortical area. The absence of cerebrovascular reactivity or the 
presence of a steal phenomenon is a stronger indicator of the severity of the disease, thus reinforcing the 
need for surgical intervention
Table 4. 
Suggested criteria for revascularization surgery.
Variable Characteristics Points
DSA Steno-occlusive lesion + Moyamoya vessels 1
Steno-occlusive lesion+ moyamoya vessels + 2
intracranial compensation routes
Steno-occlusive lesion+extra-intracranial compensation 
routs
3
MRI No signs of ischemia/hemorrhage/atrophy 0
Signs of ischemia/hemorrhage/atrophy 1
Cerebrovascular reserve 
capacity
No steal phenomenon (> − 5%) 0
Steal phenomenon (<−5%) 2
Grades 1–2: mild; Grades 3–4: moderate; Grades 5–6: severe.
Table 5. 
The Berlin grading system.
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blockers and antiepileptic medications should be continued until the day of the 
surgery. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin 
receptor blockers should be stopped a day before surgery. Patients with symp-
tomatic MMD and vaso-occlusive disease of the carotid and coronary artery, 
are usually on antiplatelet medications. Continuation of low dose aspirin in the 
perioperative period varies from center to center. In some centers, aspirin is 
continued until the day of the surgery whereas clopidogrel and other antiplatelet 
are discontinued five to seven days before surgery and bridged with low molecu-
lar weight heparin [9, 11]. Premedication with anxiolytics may be beneficial in 
pediatric patients, as crying causes hyperventilation that results in hypocarbia 
and hence, cerebral vasoconstriction and cerebral ischemia [18, 19]. Careful titra-
tion of anxiolytics is vital to reduce anxiety and on the other hand, to reduce the 
risk of cerebral vasodilation caused by hypoventilation and hypercarbia, as it may 
lead to raised intracranial pressure and cerebral hemorrhage. Adequate hydra-
tion during the preoperative period is deemed necessary to avoid compromised 
cerebral blood flow.
2.2 Intraoperative anesthesia consideration
2.2.1 Intraoperative monitoring technique
Intraoperative monitoring technique includes all routine basic physiological 
monitors also known as “Standard American Society of Anesthesiologists (ASA) 
monitors” such as Non-invasive blood pressure devices, Electrocardiography, 
Pulse oximetry for Oxygen saturation, capnography, and temperature monitoring. 
Additionally, an invasive intra-arterial catheter is inserted for continuous blood 
pressure monitoring preferably before induction to monitor and maintain the 
hemodynamics, central venous access, and Foley’s catheter for urine output. Also, 
advanced cardiac output monitoring is usually considered in patients with signifi-
cant cardiovascular and renal disease and to help in optimization of fluid status. 
However, there is limited data available on the usefulness of these cardiac output 
monitoring in intracranial bypass surgery. Likewise, cerebral function monitoring 
such as electroencephalogram (EEG) and somatosensory evoked potential (SSEP) 
have been used intraoperatively but less evidence available in the literature regard-
ing their benefits [28–30]. Lastly, the role of other monitoring technique for global 
cerebral function such as transcranial Doppler, cerebral oximetry, and jugular 
bulb oxygen saturation have been reported; however, there is paucity of evidence 
available in the literature that their use help in early detection of cerebral ischemia 
or favorably impact the outcome [31–33].
2.2.2 Role of indocyanine green (ICG)
Indocyanine green video angiography (ICG-VA) is used in intracranial bypass 
surgery which is a non-invasive technique to assess the patency of a bypass 
graft or anastomosis [34–36]. ICG is a preservative-free powder (25 mg), which 
is diluted with 10 ml of distilled water (2.5 mg/ml). The technique requires 
intravenous injection of ICG and the direct application of a microscope with an 
integrated ICG camera on the operative field. The standard dose range from 5 to 
25 mg. Intraoperative ICG-VA facilitates the identification of potential recipient 
vessels and detection of pathological flow patterns [35]. The main disadvantage 
of ICG angiogram is the failure to visualize deeper vasculatures. ICG injection 
may cause erroneous readings on the pulse oximeter and can cause anaphylactic 
reactions [37, 38].
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2.2.3 Choice of anesthesia techniques
General anesthesia is recommended for revascularization surgery. The goal of 
anesthesia induction is to maintain hemodynamics, oxygenation, and ventilation. 
It also aims to avoid a decrease in cerebral perfusion pressure (CPP) and increased 
intracranial pressure (ICP), which are attributed to anesthetic drugs and airway 
maneuvers. The choice of induction technique for general anesthesia (intravenous 
versus inhalational agents) has been debated and depends on patient factors 
(pediatric versus adult), surgical factors (use of neurophysiologic monitoring), and 
potential for compromised or difficult airway [18, 39, 40]. Sakamoto et al. investi-
gated the perioperative course of 216 patients undergoing revascularization; they 
concluded that the incidence of postoperative ischemic events was associated with 
the severity of the disease and surgical procedure than with other factors, including 
anesthetic management (inhaled, IV, and balanced anesthesia) [40].
Sato et al. studied the effect of total intravenous anesthesia (TIVA) versus vola-
tile anesthetic on cerebral circulation in MMD and concluded that volatile agents 
might reduce the regional cortical blood flow and hence, inducing intracerebral 
steal; this was not observed with TIVA [41]. More recently, studies demonstrated 
improved outcomes when TIVA is used [42], whereas other studies have not 
shown a significant difference between TIVA versus inhalational agents in MMD 
[43]. Many centers are routinely utilizing total intravenous anesthesia (TIVA) 
with target-controlled infusion (TCI) of propofol and opioids (remifentanil) for 
the neurosurgical procedure [44]. In TCI, the infusion pumps are set to deliver 
a bolus on induction followed by a maintenance infusion based on the patient’s 
demographics. TIVA with propofol and remifentanil offers theoretical advantages 
for neurosurgical procedures such as careful and easy titration of anesthetic to 
maintain the hemodynamics intraoperatively; and most notably rapid, smooth 
emergence with early recovery of neur0cognitive function without postoperative 
nausea and vomiting. Additionally, TIVA is an anesthetic of choice in neurosurgery 
during neurophysiological monitoring (SSEP). In conclusion, more prospective 
studies are needed to determine the influence of different anesthetic techniques on 
revascularization surgery and its outcome.
2.2.4 Oxygenation and ventilation strategies
Cerebral oxygenation depends on the content of oxygen in the arterial blood, 
cerebral blood flow, and metabolic activity of brain tissue. All of these elements can 
be altered in patients with chronic cerebral ischemia. Intraoperative goals of oxy-
genation and ventilation should be maintaining normo-oxygenation and normocar-
bia [18, 19, 45]. Carbon dioxide is a potent modulator of cerebrovascular tone and 
influences the cerebral blood flow with changes in ventilation and can be a potential 
factor in determining neurologic complications perioperatively. In one systematic 
review, cerebrovascular reactivity to PaCO2 is maintained under both propofol 
and inhalational agents provided anesthetic concentration within the range used 
in clinical anesthesia [46]. Sumikawa et al., intraoperative hypocapnia (PaCo2 
30-35 mm Hg) is linked to delayed recovery of consciousness and postoperative 
neurologic deficits [47]. Therefore, one should aim at maintaining normocarbia 
with PaCO2 between 35 to 40 mm Hg.
2.2.5 Hemodynamic management
Effective and prompt hemodynamic control is crucial during the perioperative 
period. Both hypotension and hypertension have a detrimental effect on postoperative 
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outcomes. Hypotension is poorly tolerated by patients with MMD and leads to cerebral 
ischemia and thrombosis of the bypass graft postoperatively. Likewise, hypertension 
results in intracranial hemorrhage especially at the site of anastomosis either during 
or after the surgery. The incidence and extent of postoperative cerebral ischemia can 
be decreased by adopting individualized perioperative blood pressure management 
[48]. The optimal blood pressure target during surgery is not well described but the 
general recommendation is to keep the blood pressure within 10% to 20% of the 
preoperative baseline blood pressure for all patients [18, 19, 45]. Careful titration of 
anesthetic during induction and maintenance of anesthesia is critical in regulating the 
blood pressure. Any episode of hypotension (systolic less than 100 mm Hg) should be 
treated promptly with vasoactive drugs. Similarly, persistent perioperative hyperten-
sion should be controlled with drugs such as hydralazine, esmolol, or labetalol.
2.2.6 Fluid and blood products
The goal of fluid management is to maintain normovolemia and a hematocrit 
between 30 and 35% [49]. Hemodilution and polycythemia both carry the risk 
of perioperative cerebral ischemia [50]. So, careful titration and control of blood 
viscosity are vital; this is accomplished by replacing insensible losses, blood loss, and 
urine output with a combination of normal saline and 5% albumin or blood products. 
Though some studies have recommended a hypervolemia state to avoid the issues 
associated with hypotension and decreased cerebral perfusion [51]. Arterial blood 
gas, electrolyte, glucose, and hematocrit should be measured at regular intervals 
throughout the case with the target of maintaining normal values. It has been sug-
gested that hematocrit of about 30–35% balances the oxygen blood content and blood 
viscosity and promotes sufficient oxygen delivery extrapolated from the cardiac 
surgery. Advanced cardiac output monitoring is utilized in assessing volume status, 
fluid responsiveness, and guiding fluid therapy, and the need for vasopressors.
2.2.7 Temperature management
Normothermia is commonly advocated in neurosurgery to avoid post-operative 
shivering, surgical site infection, cardiac arrhythmia, acidosis, and coagulopathy. Mild 
hypothermia is considered as it offers some degree of neuroprotection against cerebral 
hypoxia and ischemia by reducing the cerebral metabolic rate. However, there have 
been few studies and no randomized clinical trials conducted. Moreover, the role of 
cerebral-protective techniques such as inducing burst suppression with the administra-
tion of propofol or barbiturates or hypothermia at the time of temporary artery clamp-
ing, is debatable and is dependent on the centers and surgeons’ preferences.
2.2.8 Analgesia
The importance of perioperative control of pain in MMD cannot be overstated. 
Pain is associated with neuroendocrine responses, resulting in an increase in cere-
bral metabolism that is detrimental to MMD. A postoperative cerebral infarction 
may be associated with inadequate pain control. Therefore, adequate perioperative 
analgesia may reduce the risk of cerebral ischemia or infarction [40]. Multimodal 
analgesia (MMA) strategy is often employed to optimize pain control and limit the 
undesired side effect simultaneously. MMA includes the use of opioids coupled 
with acetaminophen, gabapentin, or pregabalin, and non-narcotic analgesics such 
as tramadol and COX-2 inhibitors [52, 53]. The use of local anesthetic and regional 
anesthesia is also recommended. Patient-controlled analgesia can also be considered 
in the postoperative period.
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2.2.9 Regional anesthesia
Regional anesthesia offers perioperative analgesia and facilitates smooth emer-
gence. Harvey, Cushing, and George Crile, first described the role of local anesthetic 
infiltration or regional anesthetics of the scalp for craniotomies in the early 1900s 
[54]. Girvin et al. first described the scalp nerve block technique in 1986 for use dur-
ing awake craniotomy. It comprises of blocking six nerves that provide the sensory 
innervation of the scalp, on either side of the scalp, with infiltration of local anes-
thetics (2-3 ml) for each nerve. These nerves consist of the supraorbital, supratroch-
lear, zygomaticotemporal, auriculotemporal, lesser occipital, and greater occipital 
nerves, usually given bilaterally. Scalp block effectively blunts the hemodynamic 
response preoperatively. Also, scalp block has been proven to be superior over a 
sham group (with saline) in terms of hemodynamic stability and decreased anes-
thetic requirement during cranial fixation [55, 56]. Scalp block’s effect also extends 
into the postoperative period and has proved to decrease the incidence and severity 
of postoperative pain [57]. In summary, the incorporation of regional anesthesia has 
led to a smooth intraoperative course and improved postoperative patient comfort.
2.3 Emergence and extubation
The aim of emergence from anesthesia includes smooth, rapid emergence and 
extubation; also avoidance of straining, bucking, and coughing, and complete, pain-
free awakening. Use of lidocaine intra-tracheal before extubation will safeguard 
against coughing and bucking and repeat scalp block at the end of surgery. A smooth 
emergence with controlled hemodynamics is vital to prevent hemorrhagic complica-
tions and graft thrombosis. The tenuous cerebral blood supply places patients with 
MMD at increased risk of perioperative morbidity during revascularization proce-
dures because of the hemodynamic changes that may occur throughout induction, 
maintenance, and emergence. The consensus is to maintain CPP at or above the 
baseline perioperatively. The principle of neuroanesthesia care such as normoten-
sion, normovolemia, norm0-oxygenation, normocapnia, and normothermia; must 
be implemented during the emergence and post-extubation period.
2.4 Postoperative intensive care
Postoperative care of MMD patients undergoing revascularization surgery pref-
erably takes place in the intensive care unit. They need to be closely monitored for 
any hemodynamic and neurological changes, as postoperative ischemic events have 
been attributed to hemodynamic swings. Invasive monitoring to continue through-
out the journey to the ICU. It is crucial to avoid both hypotension and hypertension 
that may cause graft thrombosis and bleed respectively. Optimal control of blood 
pressure, oxygen supply, ventilation may help to prevent the incidence of periopera-
tive cerebral ischemic events.
Intravenous fluid administration to maintain normovolemia and starting aspirin 
on the first postoperative day has been recommended. Adequate analgesia is provided 
to prevent agitation and increased stress, which may affect the bypass. Postoperative 
sedation/analgesia with dexmedetomidine and fentanyl infusion is a good choice.
3. Postoperative neurological complications and outcome
Multiple risk factors have been implicated with perioperative complications 
in MMD patients, such as patient comorbidities, the severity of the disease, type 
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of surgery, type of revascularization procedure, and nonsurgical hemodynamic 
risk factors.
3.1 Cerebral ischemia
The incidence of postoperative cerebral ischemia has been reported to be 
approximately 3.5% in adult patients and 16.9% in pediatric patients [32, 58]. 
Sakamoto et al. studied the risk factors for perioperative complications in revascu-
larization surgery and found that the severity of the disease, history of TIA, and 
indirect bypass procedures were the major determinants for postoperative neuro-
logical deficits [59]. Similarly, Zhao et al. recently found that advanced Suzuki stage 
and preoperative ischemic presentation were independent risk factors for postop-
erative ischemia [60]. Lastly, The Carotid Occlusion Surgery Study (COSS) investi-
gators found that the mechanism of stroke was usually attributed to hypoperfusion 
and the occurrence of artery-to-artery emboli or thrombosis [61].
3.2 Cerebral hyperfusion syndrome (CHS)
CHS was first reported by Uno et al. in a patient with MMD after extracranial-
intracranial bypass in 1998 [62]. Since 1998, CHS has been reported in both pediat-
ric and adult MMD patients after direct revascularization surgery.
The incidence of cerebral hyperperfusion in patients with occlusive cerebrovascular 
disease is reported at 17% after bypass surgeries, and 0.4% to 20% after carotid end-
arterectomy [63]. In another study, the incidence of CHS in MMD patients after direct 
surgical revascularization was reported to be 21.5% [64]. Adult-onset, hemorrhagic 
presentation, and increased preoperative cerebral blood volume were the risk factors 
for developing CHS [63]. The most common symptoms are transient neurological 
deficits, followed by hemorrhage and seizure [65]. CHS after surgical revascularization 
is caused by an increase in the cerebral blood flow, control of blood pressure postopera-
tively is the direct way to prevent or treat CHS. Active treatment of CHS should be con-
sidered in a patient with postoperative neurologic deficits such as headache, seizure, 
or transient focal neurological deficits. The strict control of blood pressure at targets 
less than 120/80 mm Hg, and routine postoperative monitoring of cerebral blood 
flow using transcranial Doppler and dynamic imaging techniques (computerized 
tomography or magnetic resonance perfusion) to be effective in preventing permanent 
neurological sequelae secondary to cerebral hyperperfusion syndrome [63, 66].
4. Special anesthetic consideration in MMD
4.1 Anesthetic consideration in the obstetric patient with MMD
Parturients with moyamoya syndrome should be treated with tight blood pres-
sure control. Hypotension and hypertension should be avoided. Peripartum pain 
control is crucial to preventing pain-related hyperventilation and resultant cerebral 
vasoconstriction. Because cerebral aneurysms may develop with disease progres-
sion, these patients are at higher risk of intracranial hemorrhage than the general 
population. The development of cerebral aneurysms may be secondary to chronic 
hypertension or regional vessel constriction in moyamoya. Additionally, multiple 
tiny collateral arterioles develop at sites of proximal arterial occlusion which are 
prone to rupture. Hypercoagulability, venous stasis, and endothelial lesion are com-
mon in pregnancy and may contribute to stroke. Therefore, the anesthetic goals for 
a parturient with known Moyamoya syndrome are to avoid hypertension, which can 
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precipitate the hemorrhage, and avoid hypotension or hypocapnia that can reduce 
placental perfusion and the already compromised cerebral blood flow. The deci-
sion for timing and method of delivery in MMD patients is based on reducing risks 
associated with hemodynamic instability. Control of hemodynamic fluctuations, 
minimizing anxiety and pain, and Valsalva, and meticulous fluid management 
during intrapartum are the main components for maintaining optimal end-organ 
perfusion of the mother and fetus. More than 70% of parturients with MMD 
undergo an elective cesarean section. This is the delivery route of choice to prevent 
intracranial hemorrhage due to hypertension during labor. General anesthesia 
and neuraxial anesthesia have been reported as successful for the cesarean section 
[67–71]. However, both techniques are associated with sudden hypotension which 
may progress to ischemic events. General anesthesia is chosen for better control of 
hypotension (common in spinal anesthesia, leading to cerebral hypoperfusion). 
Tracheal intubation during general anesthesia may cause hypertension resulting in 
intracranial hemorrhage and general anesthesia also carries the risk of aspiration. 
Care should be taken during direct laryngoscopy to reduce sympathetic drive. Also, 
the technique could prevent hyperventilation secondary to maternal anxiety, which 
causes hypocapnia and decreases cerebral blood flow. Normotension and normo-
capnia should be the goals during general anesthesia. Vaginal delivery is considered 
in MMD patients at low risk for intracranial hemorrhage, such as those who under-
went bypass surgery or without a history of bleeding [72]. Most affected parturient 
undergo successful cesarean deliveries under neuraxial anesthesia (spinal, epidural, 
or combined spinal-epidural anesthesia), often with invasive arterial hemodynamic 
monitoring; as it provides easier monitoring for neurological changes as well as 
preventing hypertension associated with intubation during general anesthesia. 
Additionally, a multidisciplinary approach (i.e., anesthesiologist, obstetrician, fetal 
medicine, and neurosurgery) is necessary to constantly manage underlying diseases.
4.2 Anesthetic consideration in a pediatric patient with MMD
Pediatric patients with MMD have a higher baseline cerebral metabolic rate of 
oxygen consumption and thus poorly tolerate any reduction in cerebral blood flow. 
Therefore, these children should be maintained with a normal or higher than nor-
mal mean arterial pressure; normocapnia to prevent hypocapnia mediated cerebral 
vasoconstriction and also prevent hypercapnia leading to cerebral blood flow steal 
phenomenon; adequate hydration; analgesia; and normothermia [15].
Pre-operatively children have undergone workup for neurological symptoms 
such as cerebral vascular imaging (MRI or MRA) and are typically on anti-platelet 
or anti-seizure medications. Additionally, these children are on medication (such as 
midodrine) that keeps the blood pressure up as these stenotic cerebral arteries depend 
on high blood pressure, and any medication that decreases the blood pressure can be 
detrimental. Children are usually anxious from possible parental separation; may ben-
efit from the use of pre-anesthesia anxiolysis as well as the comforting presence of the 
parent in the operating room or virtual reality (music etc). Crying can lead to hyper-
ventilation and hypocapnia. Additionally, these patients must be kept well hydrated 
to allow for adequate blood volume in the context of anesthesia-induced vasodilation. 
Since these patients are nil-per-oral, they should be given intravenous fluids of around 
one and half times their maintenance requirements pre-operatively. Also, a thorough 
history and physical examination necessary to determine any other associated condi-
tions such as sickle cell disease, neurofibromatosis type 1, and trisomy 21.
Intra-operatively, these children may be induced intravenously if they have an 
intravenous line in place or by inhalation. Outcomes for induction are similar for 
both these approaches provided the blood pressure and ventilation is maintained. 
Moyamoya Disease
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Intravenous maintenance with combined propofol and remifentanil may be bet-
ter compared to inhalational maintenance as studies have shown reduced cerebral 
oxygenation with inhalational agents perhaps due to the cerebral steal phenomenon 
[42, 43, 73]. Phenylephrine infusion is utilized to maintain the mean arterial pres-
sure. Hyperventilation and hypoventilation must be avoided as they are associated 
with negative outcomes. Sympathetic response to laryngoscopy and intubation 
must be blunted with intravenous lidocaine, opioid, or short-acting beta-blockers. 
To maintain blood pressure and ventilation, it is essential to monitor these patients 
with an invasive arterial line, pulse oximetry, capnography, ECG, and temperature. 
Additionally, intra-operative EEG is recommended. A urine catheter to monitor 
urine output with careful monitoring of fluid balance is needed to maintain normo-
volemia. Central venous access is rarely required but can be utilized in patients with 
difficult intravenous access. Intravenous fluids must not contain glucose.
Post-operatively, smooth extubation with adequate analgesia, hydration, and nor-
mothermia is necessary as not to potentially jeopardize cerebral blood flow. Patients 
who have undergone indirect revascularization are still at risk of post-operative 
stroke. Analgesia must be maintained usually with an opioid-based patient-controlled 
technique supplemented with other analgesics such as acetaminophen. Anti-emetics 
must be given to prevent nausea or vomiting. Recovery must be ideally carried out by 
trained pediatric intensive care nurses experienced in managing Moyamoya disease. 
Transfer of care to a high dependency unit is recommended after recovery.
4.3  Anesthetic consideration for MMD patients going for non-revascularization 
surgery
4.3.1 Laparoscopic surgery
Laparoscopic surgery has gained tremendous popularity in recent years. The 
key element in laparoscopic surgery is the creation of pneumoperitoneum with 
carbon dioxide insufflation. The physiological changes especially cardiopulmonary 
alterations during laparoscopic surgery occur mainly due to the creation of pneu-
moperitoneum and positioning of the patient. Similarly, cerebral hemodynamic 
changes (including changes in cerebral perfusion and intracranial pressure) also 
occur during the creation of pneumoperitoneum and positioning of the patient. 
Anesthesia goals for MMD patients undergoing laparoscopic surgery are to allow 
physiological changes during surgery with minimal effects on the body’s vital 
organs and rapid and smooth recovery. Induction of anesthesia should be carried 
out with careful titration of anesthetic drugs to avoid hemodynamic fluctuations. 
Airway manipulation should be minimized to avoid sympathetic surge. Nakanishi 
et al. used Laryngeal mask airway ProSeal successfully in a MMD patient who 
underwent laparoscopic cholecystectomy [74]. The author proposes the use of LMA 
ProSeal as an effective alternative with minimal hemodynamic change, compared 
with tracheal intubation [75]. Moreover, Lee et al. reported a case of intracranial 
hemorrhage during laparoscopic cholecystectomy due to unrecognized MMD [76]. 
Hence, rigorous ventilatory management utilizing End-tidal CO2 and arterial CO2 
during pneumoperitoneum and arterial blood pressure for continuous monitoring 
of hemodynamic changes is mandatory. The intraoperative aim is to maintain blood 
pressure, oxygen saturation, ventilation, and smooth emergence from anesthesia.
4.3.2 Cardiac surgery
Patients with MMD undergoing cardiac surgery requiring cardiopulmonary 
bypass (CPB) pose considerable anesthetic challenges. CPB is a technique in which a 
machine temporarily takes over the function of the heart and lung.
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CPB in moyamoya patients has a high risk of decreasing cerebral perfusion pressure 
due to the perfusion pressure variability in the initial stages of CPB and non-pulsatile 
flow. Moreover, the risk of hypocapnic cerebral vasoconstriction and hypercapnic 
cerebral steal is a well-recognized phenomenon. Preserving the autoregulation of the 
cerebral blood flow is key to prevent cerebral ischemia. Case report proposes the use 
of an Intra-aortic balloon pump (IABP) that produces pulsatile flow which facilitates 
maintaining a higher perfusion pressure (mean arterial pressure > 80 mm Hg) and 
reduces the vasoconstrictors’ requirement [77–79]. Regional cerebral oxygen saturation 
(rSO2) monitoring for cerebral blood flow; is a useful tool and provides real-time cere-
bral blood flow; the goal is to keep cerebral saturation at 80% of the baseline value. The 
key strategy is to keep the blood pressure, PaCO2, hematocrit, and body temperature to 
normal and should be adjusted rigorously intraoperatively. Off-pump coronary artery 
bypass (OPCAB) is a safe procedure that avoids the risk of CPB related hypotensive 
brain ischemia, for multi-vessel coronary patients with moyamoya disease [80, 81].
5. Conclusion
Moyamoya disease (MMD) is a unique, slowly progressive cerebral vasculopa-
thy with an incidence of 0.09–10/100,000 individuals. It is highly prevalent in 
East Asia. It has an unknown etiology and classically presents with symptoms of 
headaches, transient ischemic attacks such as dysarthria, hemiparesis, cognitive 
decline, aphasia, and seizures. Early diagnosis and early treatment are effective in 
preventing further deterioration. Medical treatment is aimed at managing symp-
toms and typically includes anti-seizure, antihypertensive, and antiplatelet therapy. 
Surgical revascularization is the cornerstone in treating MMD patients to reduce 
further ischemic insults and neurological deterioration. Its unique pathophysiology 
requires anesthesiologists to strategize an individualized anesthetic plan and close-
in line communications with the neurosurgical team. Premedication is essential in 
pediatric patients undergoing revascularization surgery as the goal is to avoid cry-
ing and hyperventilation which provokes cerebral vasoconstriction. Perioperative 
management of moyamoya disease has a direct influence on the outcomes of the 
surgery. The key goals of perioperative management are maintenance of normoten-
sion, normovolaemia, normocapnia and normothermia, and adequate analgesia. 
Postoperatively, patients are admitted to the intensive care unit for close hemody-
namic assessment and timely neurological assessment. Effective analgesia and fluid 
resuscitation must be employed postoperatively. Antiepileptic drugs are continued 
perioperatively, and antiplatelet agents are started postoperatively.
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